Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells

No AccessJournal of Urology1 Sep 1990Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells Cary N. Robertson, W. Marston Linehan, Harvey I. Pass, Leonard G. Gomella, Gabriel P. Haas, Arlene Berman, Maria Merino, and Steven A. Rosenberg Cary N. RobertsonCary N. Robertson , W. Marston LinehanW. Marston Linehan , Harvey I. PassHarvey I. Pass , Leonard G. GomellaLeonard G. Gomella , Gabriel P. HaasGabriel P. Haas , Arlene BermanArlene Berman , Maria MerinoMaria Merino , and Steven A. RosenbergSteven A. Rosenberg View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)39537-XAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail A total of 63 patients with metastatic renal cell carcinoma with the primary kidney tumor in place was accepted as candidates for immunotherapy at the Surgery Branch of the National Cancer Institute. Of the 63 patients 54 underwent nephrectomy and 9 were treated with the primary kidney tumor in place. Many of the patients underwent associated procedures, such as regional lymphadenectomy (11), venacavotomy with extraction of tumor thrombus (9), hepatic resection (2), pulmonary wedge resection (2), cholecystectomy (2), splenectomy (2), distal pancreatectomy (1), omentectomy (1) and contralateral adrenalectomy (1). Of the 54 patients 20 were not able to enter therapy because of tumor-related (17) or other medical (3) reasons that developed between the operation and therapy, while 34 were able to receive immunotherapy postoperatively. The 20 patients who were treated with either high dose interleukin-2 or interleukin-2 plus lymphokine activated killer cells soon postoperatively (mean 2.1 months) were able to tolerate roughly the same amount of interleukin-2 as the 74 who had undergone nephrectomy before referral to our institute and who were treated for a mean of 22 months after nephrectomy. Further studies, including a prospective, randomized trial, will be required to define the role of nephrectomy in patients with advanced renal cell carcinoma before treatment with interleukin-2 based immunotherapies. © 1990 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byKaram J, Ahrar K, Wood C, Jonasch E, Vikram R, Romero C, Tannir N and Matin S (2018) Radio Frequency Ablation of Renal Tumors in Patients With Metastatic Renal Cell CarcinomaJournal of Urology, VOL. 184, NO. 5, (1882-1887), Online publication date: 1-Nov-2010.Krambeck A, Leibovich B, Lohse C, Kwon E, Zincke H and Blute M (2018) The Role of Nephron Sparing Surgery for Metastatic (pM1) Renal Cell CarcinomaJournal of Urology, VOL. 176, NO. 5, (1990-1995), Online publication date: 1-Nov-2006.FLANIGAN R, MICKISCH G, SYLVESTER R, TANGEN C, VAN POPPEL H and CRAWFORD E (2018) Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, VOL. 171, NO. 3, (1071-1076), Online publication date: 1-Mar-2004.MOTZER R and RUSSO P (2018) SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, VOL. 163, NO. 2, (408-417), Online publication date: 1-Feb-2000.SHIRAKAWA T, GARDNER T, KO S, BANDER N, WOO S, GOTOH A, KAMIDONO S, CHUNG L and KAO C (2018) CYTOTOXICITY OF ADENOVIRAL-MEDIATED CYTOSINE DEAMINASE PLUS 5-FLUOROCYTOSINE GENE THERAPY IS SUPERIOR TO THYMIDINE KINASE PLUS ACYCLOVIR IN A HUMAN RENAL CELL CARCINOMA MODELJournal of Urology, VOL. 162, NO. 3 Part 1, (949-954), Online publication date: 1-Sep-1999.LEVY D, SWANSON D, SLATON J, ELLERHORST J and DINNEY C (2018) TIMELY DELIVERY OF BIOLOGICAL THERAPY AFTER CYTOREDUCTIVE NEPHRECTOMY IN CAREFULLY SELECTED PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, VOL. 159, NO. 4, (1168-1173), Online publication date: 1-Apr-1998.Walther M, Yang J, Pass H, Linehan W and Rosenberg S (2018) CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, VOL. 158, NO. 5, (1675-1678), Online publication date: 1-Nov-1997.Fujioka T, Hasegawa M, Ogiu K, Matsushita Y, Sato M and Kubo T (2018) Antitumor Effects of Angiogenesis Inhibitor O-(Chloroacetyl-Carbamoyl) Fumagillol (TNP-470) against Murine Renal Cell CarcinomaJournal of Urology, VOL. 155, NO. 5, (1775-1778), Online publication date: 1-May-1996.Schomer N and Mohler J (2018) Partial Adrenalectomy for Renal Cell Carcinoma With Bilateral Adrenal MetastasesJournal of Urology, VOL. 153, NO. 4, (1196-1198), Online publication date: 1-Apr-1995.Walther M and Linehan W (2018) Editorial CommentsJournal of Urology, VOL. 149, NO. 1, (21-22), Online publication date: 1-Jan-1993.Spencer W, Linehan W, Walther M, Haas G, Lotze M, Topalian S, Yang J, Merino M, Lange J, Pockaj B and Rosenberg S (2018) Immunotherapy with Interleukin-2 and α-Interferon in Patients with Metastatic Renal Cell Cancer with in Situ Primary Cancers: A Pilot StudyJournal of Urology, VOL. 147, NO. 1, (24-30), Online publication date: 1-Jan-1992.deKernion J (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 1, (30-30), Online publication date: 1-Jan-1992. Volume 144Issue 3September 1990Page: 614-617 Advertisement Copyright & Permissions© 1990 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Cary N. Robertson More articles by this author W. Marston Linehan More articles by this author Harvey I. Pass More articles by this author Leonard G. Gomella More articles by this author Gabriel P. Haas More articles by this author Arlene Berman More articles by this author Maria Merino More articles by this author Steven A. Rosenberg More articles by this author Expand All Advertisement PDF downloadLoading ...